ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Q1 FY27 consolidated revenue fell 19% YoY to ₹93.7 Cr due to standalone institutional order base effects. Gross margins expanded 1,000bps to 50.6%, though consolidated PAT remained negative at ₹(3.6) Cr.
Bharat Parenterals reported flat FY26 consolidated revenue of ₹345.4cr but a 6x EBITDA surge to ₹15.8cr. Transition year focused on regulatory clearances and scaling subsidiaries like Innoxel and Varenyam.
Bharat Parenterals calls FY26 a 'bridge year' of transition, clearing regulatory hurdles and scaling subsidiaries despite flat consolidated revenue of ₹345.4 cr. Growth in high-margin subsidiaries Inoxxel and Verineum offset a 23% decline in standalone exports.
Bharat Parenterals FY26 results show a transition phase with consolidated revenue of ₹345.4Cr and a PAT loss of ₹27.3Cr, driven by heavy R&D and subsidiary investment.